This CME post-conference review and analysis will highlight therapeutic advances in the management of patients with gastrointestinal cancer, including data presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2022. The expert faculty will analyze the latest therapeutic advances for the treatment and management of gastrointestinal (GI) cancer as presented at ASCO GI 2022. They will also discuss how to apply new data and therapeutic advances into guideline-driven treatment strategies to improve the care of patients with GI cancer, with faculty panel discussion throughout. Upon completion of this activity, learners will be better equipped to improve outcomes and quality of life in patients with gastrointestinal cancer.
Oncologists, gastroenterologists, surgeons, physician assistants, and all other HCPs involved in the management of patients with gastrointestinal cancer.
- Review and analyze the latest therapeutic advances for the treatment and management of GI cancer as presented and explored at ASCO GI 2022
- Apply new data and therapeutic advances into guideline-driven treatment strategies to improve the care of patients with GI cancer, including—where appropriate—with COVID-19 considerations
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Suneel Kamath, MD||Consultant/Advisor: Exelixis, Inc.; Guardant Health, Inc.; Tempus|
|Pashtoon Kasi, MD||Consultant/Advisor: AstraZeneca Pharmaceuticals; Axiom Healthcare Strategies; Bayer HealthCare Pharmaceuticals Inc.; Boston Healthcare Associates, Inc.; Delcath Systems, Inc.; Exact Sciences Corporation; Foundation Medicine, Inc.; IPBA; Ipsen Pharma; Lilly; Merck & Co, Inc.; Natera, Inc; QED Therapeutics, Inc.; Servier Pharmaceuticals LLS; Tempus
Grant/Research Support: Advanced Accelerator Applications, A Novartis Company; AstraZeneca Pharmaceuticals; BTG; TerSera Therapeutics LLC
|Dale Shepard, MD||Consultant/Advisor: Sanofi
Grant/Research Support: Amgen Inc.; Astellas Pharma Inc.; Boehringer Ingelheim International GmbH; CompuGain LLC; Conjupro Biotherapeutics, Inc.; Deciphera Pharmaceuticals, LLC; Harpoon Therapeutics; Inhibrx, Inc.; Lilly; MabSpace Biosciences Co., Ltd.; Pionyr Immunotherapeutics, Inc.; PsiOxus Therpeutics Inc.; RAM Pharma, Inc.; Shanghai Pharma Biotherapeutics USA Inc.; Vigeo Therapeutics
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bayer HealthCare Pharmaceuticals Inc.do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 80% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].